Almac Diagnostics Partners with Merck, MRC on Companion Diagnostics Project | GenomeWeb

By Justin Petrone

Almac Diagnostics last week said it will collaborate with Merck KGaA and the UK's Medical Research Council on a study of potential biomarkers of response to the cancer drug Erbitux (cetuximab).

The deal is the latest in a string of agreements that have paired the Disease Specific Array maker with major pharmaceutical companies to develop biomarkers that can later be used in companion diagnostics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.